Current and Emerging Biologics for Ulcerative Colitis
2
조회
0
다운로드
8
인용
0
참고문헌
키워드
초록
Conventional medical treatment for ulcerative colitis canhave limited efficacy or severe adverse reactions requiringadditional treatment or colectomy. Hence, different biologicalagents that target specific immunological pathways are beinginvestigated for treating ulcerative colitis. Anti-tumor necrosisfactor (TNF) agents were the first biologics to be usedfor treating inflammatory bowel disease. For example, infliximaband adalimumab, which are anti-TNF agents, are beingused for treating ulcerative colitis. Recently, golimumab,another anti-TNF agent, and vedolizumab, an anti-adhesiontherapy, have been approved for ulcerative colitis by the U.S. Food and Drug Administration. In addition, new medicationssuch as tofacitinib, a Janus kinase inhibitor, and etrolizumab,another anti-adhesion therapy, are emerging as therapeuticagents. Therefore, there is a need for further studies toselect appropriate patient groups for these biologics and toimprove the outcomes of ulcerative colitis treatment throughappropriate medical usage.
Abstract
Conventional medical treatment for ulcerative colitis can have limited efficacy or severe adverse reactions requiring additional treatment or colectomy. Hence, different biological agents that target specific immunological pathways are being investigated for treating ulcerative colitis. Anti-tumor necrosis factor (TNF) agents were the first biologics to be used for treating inflammatory bowel disease. For example, infliximab and adalimumab, which are anti-TNF agents, are being used for treating ulcerative colitis. Recently, golimumab, another anti-TNF agent, and vedolizumab, an anti-adhesion therapy, have been approved for ulcerative colitis by the U.S. Food and Drug Administration. In addition, new medications such as tofacitinib, a Janus kinase inhibitor, and etrolizumab, another anti-adhesion therapy, are emerging as therapeutic agents. Therefore, there is a need for further studies to select appropriate patient groups for these biologics and to improve the outcomes of ulcerative colitis treatment through appropriate medical usage.
참고문헌 (35)
- Aratari A, "Colectomy rate in acute severe ulcerative colitis in the infliximab era", Dig Liver Dis, 40, pp.821~826 (2008)
- Turner D, "Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression", Clin Gastroenterol Hepatol, 5, pp.103~110 (2007)
- Stange EF, "The European consensus on ulcerative colitis:new horizons?", Gut, 57, pp.1029~1031 (2008)
- 최창환, "궤양성 대장염 치료 가이드라인", Intestinal research, 10(1), pp.1~25 (2012), 대한장연구학회
- Feagan BG, "Vedolizumab as induction and maintenance therapy for ulcerative colitis", N Engl J Med, 369, pp.699~710 (2013)
- Sandborn WJ, "Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis", N Engl J Med, 367, pp.616~624 (2012)
- Stidham RW, "Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factoralpha agents for the treatment of ulcerative colitis", Aliment Pharmacol Ther, 39, pp.660~671 (2014)
- Tracey D, "Tumor necrosis factor antagonist mechanisms of action: a comprehensive review", Pharmacol Ther, 117, pp.244~279 (2008)
- Probert CS, "Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial", Gut, 52, pp.998~1002 (2003)
- Rutgeerts P, "Infliximab for induction and maintenance therapy for ulcerative colitis", N Engl J Med, 353, pp.2462~2476 (2005)
- Reinisch W, "Infliximab concentration and clinical outcome in patients with ulcerative colitis", Gastroenterology, 142(5), pp.114~ (2012)
- Sandborn WJ, "Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab", Gastroenterology, 137, pp.1250~1260 (2009)
- Lichtenstein GR, "Serious infections and mortality in association with therapies for Crohn’s disease:TREAT registry", Clin Gastroenterol Hepatol, 4, pp.621~630 (2006)
- Panaccione R, "Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis", Gastroenterology, 146, pp.392~400 (2014)
- Colombel JF, "Infliximab, azathioprine, or combination therapy for Crohn’s disease", N Engl J Med, 362, pp.1383~1395 (2010)
- Hart AL, "Review article: the optimal medical management of acute severe ulcerative colitis", Aliment Pharmacol Ther, 32, pp.615~627 (2010)
- Järnerot G, "Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study", Gastroenterology, 128, pp.1805~1811 (2005)
- Laharie D, "Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial", Lancet, 380(9857), pp.1909~1915 (2012)
- Lee KM, "Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study", J Gastroenterol Hepatol, 28, pp.1829~1833 (2013)
- Park SH, "Severe disease activity and cytomegalovirus colitis are predictive of a nonresponse to infliximab in patients with ulcerative colitis", Dig Dis Sci, 58, pp.3592~3599 (2013)
- 서현일, "The Effect of Infliximab on Patients with Ulcerative Colitis in Korea", Intestinal research, 12(3), pp.214~220 (2014), 대한장연구학회
- Miheller P, "Anti-TNF trough levels and detection of antibodies to anti-TNF in inflammatory bowel disease: are they ready for everyday clinical use?", Expert Opin Biol Ther, 12, pp.179~192 (2012)
- Afif W, "Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease", Am J Gastroenterol, 105, pp.1133~1139 (2010)
- Bendtzen K, "Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of antitumour necrosis factor-alpha antibodies", Scand J Gastroenterol, 44, pp.774~781 (2009)
- Reinisch W, "Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial", Gut, 60, pp.780~787 (2011)
- Sandborn WJ, "Adalimumab induces and maintains clinical remission in patients with moderateto-severe ulcerative colitis", Gastroenterology, 142, pp.257~265 (2012)
- Feagan BG, "Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis", Gastroenterology, 146, pp.110~118 (2014)
- Sandborn WJ, "Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis", Gastroenterology, 146, pp.85~95 (2014)
- Sandborn WJ, "Subcutaneous golimumab maintains clinical response in patients with moderate-tosevere ulcerative colitis", Gastroenterology, 146, pp.96~109 (2014)
- Chen Y, "Asymptomatic reactivation of JC virus in patients treated with natalizumab", N Engl J Med, 361, pp.1067~1074 (2009)
- Targan SR, "Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE Trial", Gastroenterology, 132, pp.1672~1683 (2007)
- Vermeire S, "Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial", Lancet, 384, pp.309~318 (2014)
- Vermeire S, "Differentiation between etrolizumab (rhumab beta7) and placebo in the eucalyptus phase II randomized double-blind placebo-controlled induction study to evaluate efficacy and safety in patients with refractory moderateto-severely active ulcerative colitis", Gastroenterology, 144(5), pp.S36~ (2013)
- Stenke E, "Ulcerative colitis: management in adults, children and young people (NICE Clinical Guideline CG166)", Arch Dis Child Educ Pract Ed, 99, pp.194~197 (2014)
- "Seoul:Health Insurance Review & Assessment Service" (2013)[URL]